Venous thromboembolism incidence in hematologic malignancies

Area of Science:

• Hematology
• Oncology
• Thrombosis Research

Background:

• Venous thromboembolism (VTE) is a critical complication in cancer patients, impacting morbidity and mortality.
• Existing VTE risk assessment models inadequately represent hematologic malignancies.
• Therapies for hematologic cancers can be inherently thrombogenic, necessitating specific risk evaluation.

Purpose of the Study:

• To review the incidence of VTE across various hematologic malignancies.
• To provide practical guidance for VTE prevention and management in this patient subgroup.
• To highlight the unique VTE risk factors associated with hematologic cancers and their treatments.

Main Methods:

• Literature review summarizing VTE incidence in leukemia, lymphoma, multiple myeloma, and stem cell transplantation.
• Analysis of risk factors including specific treatments (e.g., L-asparaginase, immunomodulatory agents), age, comorbidities, central venous catheters, and graft-versus-host disease.
• Synthesis of current understanding of VTE in the context of hematologic malignancies.

Main Results:

• Leukemia VTE risk is influenced by L-asparaginase, age, comorbidities, and central venous catheters.
• Acute promyelocytic leukemia patients face high VTE and bleeding risks.
• Aggressive lymphomas present a ~10% VTE incidence; multiple myeloma patients on immunomodulatory drugs have elevated risk.
• Allogeneic stem cell transplantation, especially with graft-versus-host disease, increases thrombosis risk.

Conclusions:

• Hematologic malignancies represent a distinct population with unique VTE risks and management needs.
• Current VTE risk stratification requires enhancement to include specific hematologic cancer contexts.
• Evidence-based strategies are crucial for optimizing VTE prevention and treatment in patients with hematologic cancers.